Status:
TERMINATED
REBEAT Resynchronisation and Beta-Blocker European Trial
Lead Sponsor:
Guidant Corporation
Conditions:
Heart Failure
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
This protocol will evaluate the effect of cardiac resynchronization therapy (CRT) combined with beta-blocker therapy in patients with symptomatic heart failure in whom beta-blocker therapy was either ...
Detailed Description
The purpose of this investigation is to evaluate the effect of CRT combined with beta-blocker therapy in patients with symptomatic heart failure in whom beta-blocker therapy was either not tolerated o...
Eligibility Criteria
Inclusion
- Symptomatic heart failure and indication for cardiac resynchronization therapy (CRT), Hemodynamic stability with documented intolerance to beta-blocker therapy or treatment with beta-blocking agents at sub-optimal dosages (\<25% of optimal dosage).
Exclusion
- chronic atrial fibrillation; indications for permanent antibradycardia pacing; mechanical tricuspid valve; Severe aortic stenosis or other primary valve disease causing cardiomyopathy
Key Trial Info
Start Date :
April 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 1 2007
Estimated Enrollment :
354 Patients enrolled
Trial Details
Trial ID
NCT00305526
Start Date
April 1 2006
End Date
July 1 2007
Last Update
August 9 2007
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Spedali Civili di Brescia
Brescia, Italy, 25100
2
Istituto clinico Humanitas
Milan, Italy
3
Cardiocentro Ticino
Lugano, Switzerland